Iomai (IOMI) Reports a Full-Year Loss
Iomai Corporation (Nasdaq: IOMI) reports a FY07 loss of $1.16, 4 cents better than estimates. Revenues were $10.67 million vs. $10.92 million consensus.
Iomai Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of vaccines and immune system stimulants delivered to the skin via a needle-free technology called transcutaneous immunization (TCI). [SM]
Iomai Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of vaccines and immune system stimulants delivered to the skin via a needle-free technology called transcutaneous immunization (TCI). [SM]
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
